Orchestra BioMed Showcases AVIM Therapy and Virtue SAB at ICI Meeting

Reuters12-08
<a href="https://laohu8.com/S/OBIO">Orchestra BioMed</a> Showcases AVIM Therapy and Virtue SAB at ICI Meeting

Orchestra BioMed Holdings Inc. participated in the 2025 Innovation in Cardiology Intervention (ICI) meeting in Tel Aviv, Israel, where the company delivered three presentations. These included two focused on Atrioventricular Interval Modulation Therapy (AVIM Therapy) and its ongoing strategic collaboration with Medtronic for the treatment of uncontrolled hypertension in pacemaker patients, and one on the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), highlighting its novel drug delivery technology for coronary artery disease and updates from the Virtue IDE trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597959-en) on December 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment